Papyrus Therapeutics

West Chester, United States Founded: 2016 • Age: 10 yrs
Develops therapies for tumor suppression in various cancers through scientific research.
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors - Known backers
Products 1 Services tracked
Competitors 5 Brand Intelligence

About Papyrus Therapeutics

Papyrus Therapeutics is a company based in West Chester (United States) founded in 2016 by Hani Gabra and Paul Blake. It operates as a B2B. Papyrus Therapeutics offers products and services including Extracellular Tumor Suppressor Therapies. Papyrus Therapeutics operates in a competitive market with competitors including ChemoTech, Nativis, IGEA and RanD, among others.

  • Headquarter West Chester, United States
  • Founders Hani Gabra, Paul Blake
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    Not available
  • Investors
    Not available
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Papyrus Therapeutics

Papyrus Therapeutics offers a comprehensive portfolio of products and services, including Extracellular Tumor Suppressor Therapies.

Product name locked
Category locked
Primary

Therapies aimed at suppressing tumors in multiple cancers through research.

Funding Insights of Papyrus Therapeutics

Premium access

Detailed funding history for Papyrus Therapeutics

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Papyrus Therapeutics

Investments
Premium access

Investment portfolio details for Papyrus Therapeutics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Papyrus Therapeutics

Premium access

Detailed financials for Papyrus Therapeutics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Papyrus Therapeutics Comparisons

Papyrus Therapeutics Primary company
Description
Develops therapies for tumor suppression in various cancers ...
Location
West Chester, United States
Founded Year
2016
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Papyrus Therapeutics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Papyrus Therapeutics

Papyrus Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ChemoTech, Nativis, IGEA and RanD, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Developer of electroporation devices for the treatment of cancer
Locked Locked Locked
Developer of a therapeutic device for the treatment of cancer
Locked Locked Locked
Orthopedic medical devices to promote reparative osteogenesis and joint protection
Locked Locked Locked
Medical devices for surgical oncology are developed using extracorporeal technologies.
Premium access

Detailed competitors of Papyrus Therapeutics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Papyrus Therapeutics

Premium access

Complete news archive for Papyrus Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Papyrus Therapeutics

Papyrus Therapeutics was founded in 2016.

Papyrus Therapeutics is headquartered in West Chester, United States. It is registered at West Chester, Pennsylvania, United States.

Paul Blake is the current CEO of Papyrus Therapeutics. They have also founded this company.

Papyrus Therapeutics specializes in creating extracellular tumor suppressor therapies to treat multiple types of cancers, focusing on innovative scientific research and development. The company operates from West Chester, PA, in North America, and London, UK, in Europe, engaging in oncology advancements. They aim to contribute to medical treatments by addressing tumor suppression, though specific clients or partnerships are not detailed.

Papyrus Therapeutics's top competitors include ChemoTech, Nativis and RanD.

Papyrus Therapeutics offers Extracellular Tumor Suppressor Therapies.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available